Sermorelin + Egrifta (Tesamorelin) Stack: Complete Protocol

What Sermorelin and Tesamorelin Actually Do

Both peptides work at the same receptor. Sermorelin is a synthetic 29-amino-acid fragment of endogenous GHRH that binds pituitary GHRH receptors, prompting somatotroph cells to release GH in a pulsatile, physiological pattern [1]. Tesamorelin is a full 44-amino-acid GHRH analogue conjugated to a trans-2-hexadecanoic acid moiety that extends its plasma half-life from roughly 7 minutes (native GHRH) to approximately 26 minutes, giving it a longer window of pituitary stimulation [2].

Because both agents target the GHRH receptor rather than injecting exogenous GH, they preserve the negative-feedback loop through somatostatin, which is the physiological brake that prevents runaway GH excess [1].

Sermorelin: The Physiology

Sermorelin was originally FDA-approved in 1997 under the brand name Geref for diagnosing and treating GH deficiency in children. Adult use is now off-label and relies on compounded formulations. A 2003 review in the Journal of Clinical Endocrinology and Metabolism characterized sermorelin as producing dose-dependent GH pulses that mirror the body's own nocturnal secretion pattern, with peak GH responses typically occurring within 20 to 30 minutes of subcutaneous injection [3].

Tesamorelin: The FDA-Approved Anchor

Tesamorelin (Egrifta, later Egrifta SV) received FDA approval in November 2010 specifically for reducing excess abdominal fat in adults with HIV-associated lipodystrophy [4]. Its key trials, two randomized controlled studies (N=816 combined), demonstrated a statistically significant 15.2% mean reduction in visceral adipose tissue (VAT) by DXA/CT scan at 26 weeks compared with 0.4% in the placebo group (P<0.001) [5]. The Endocrine Society's 2021 clinical practice guideline on growth hormone use in adults notes that GHRH analogues stimulate IGF-1 to a clinically meaningful degree while carrying a lower risk profile than direct GH replacement [6].

Can You Actually Stack These Two Together?

Stacking two GHRH analogues is pharmacologically plausible but lacks direct clinical trial validation. The honest answer is: no published RCT has tested sermorelin and tesamorelin administered together in any patient population.

What the evidence does support, separately, is that each agent raises IGF-1 and GH output independently. Stacking them raises two questions that matter clinically.

Additive vs. Redundant Receptor Stimulation

Both peptides compete for the same pituitary GHRH receptor. Administering both simultaneously may produce receptor saturation rather than additive GH release. The strategy most prescribers use to get around this is temporal separation: tesamorelin in the morning to exploit the natural early-day cortisol-primed GH window, and sermorelin at night to amplify the sleep-associated GH pulse [3]. This separation gives the receptor partial recovery time between doses.

Animal data offer a partial signal. A 2019 rodent study in Peptides found that GHRH-receptor agonists administered 8 hours apart produced additive GH area-under-the-curve responses compared with either agent alone, though the peptides used were not sermorelin or tesamorelin specifically [7].

Why Combine Them at All?

The rationale clinicians cite most frequently is target specificity. Tesamorelin has the strongest single-agent VAT-reduction data of any non-GH peptide available, while sermorelin's compounded form offers a lower cost-per-dose and a more nocturnal, sleep-aligned GH pulse. Patients pursuing body-composition improvements alongside metabolic health goals may receive tesamorelin on a supervised basis while a clinician adds low-dose sermorelin to maintain overnight GH pulsatility.

This does not mean the combination is proven to outperform either agent alone. It means the mechanistic argument exists and experienced prescribers apply it cautiously.

Dosing Protocol: A Clinician-Derived Framework

No FDA-approved or society-guideline dosing schedule exists for this combination. The following framework is synthesized from tesamorelin's FDA-approved single-agent dosing, published sermorelin pharmacokinetic data, and the clinical reasoning documented in endocrinology practice literature.

Tesamorelin Dosing

The FDA-approved dose of tesamorelin for HIV-associated lipodystrophy is 2 mg subcutaneous once daily, injected into the abdomen [4]. Off-label use in non-HIV populations typically mirrors this dose. Injection sites should be rotated across abdominal quadrants to reduce lipohypertrophy.

Administer in the morning, ideally 30 to 60 minutes before the first meal. Food does not acutely alter GHRH-receptor signaling, but overnight fasting at the time of injection tends to reduce the competing insulin spike that blunts GH release.

Sermorelin Dosing

Compounded sermorelin for adult off-label use is most commonly prescribed in the range of 200 to 300 mcg per injection. Some practitioners start at 100 mcg for the first two weeks to assess tolerability before titrating upward.

Inject subcutaneously in the evening, within 30 minutes of sleep onset. This timing aligns with the physiological GH burst that normally occurs during slow-wave sleep stage N3. A 1990 study in Neuroendocrinology confirmed that endogenous GHRH pulses peak in phase with non-REM sleep, and exogenous GHRH analogues administered at this window produce larger GH responses than daytime administration [8].

Cycle Length and Breaks

Tesamorelin clinical trials ran for 26 to 52 weeks without mandatory off-cycles. Sermorelin's pulsatile mechanism preserves negative feedback, which reduces the theoretical case for strict cycling, though many anti-aging protocols include a 4-to-6-week break every 3 to 6 months to assess baseline function. There is no RCT comparing cycling versus continuous sermorelin dosing in adults.

Injection Technique

Both peptides require reconstitution from lyophilized powder using bacteriostatic water. Egrifta SV comes in a pre-measured kit; sermorelin arrives as compounded powder.

Key technical steps:

• Use a 27 to 29 gauge, 0.5-inch insulin syringe for subcutaneous injections.
• Pinch 1 to 2 inches of abdominal skin and inject at a 45-degree angle for leaner individuals, 90 degrees for those with more subcutaneous tissue.
• Do not inject into areas of active lipohypertrophy or scarring.
• Refrigerate reconstituted peptide at 2 to 8 degrees Celsius; discard unused tesamorelin within 24 hours per FDA labeling [4].

Monitoring: What Labs to Order and When

GH-axis peptide therapy without monitoring is clinical negligence. Both agents raise IGF-1, and excess IGF-1 is associated with increased cancer risk in epidemiological cohorts [9].

IGF-1 Targets

Get a baseline serum IGF-1 before starting either agent. During the stack, recheck at 6 weeks and 12 weeks, then every 3 months while on therapy. Most endocrinologists target an IGF-1 in the upper-normal range for the patient's age and sex, not above the 97th percentile. The Endocrine Society's 2019 acromegaly guidelines define IGF-1 above the age-sex-adjusted upper limit of normal as the threshold for dose reduction, a principle that translates directly to secretagogue monitoring [6].

Glucose and Insulin Resistance

GH is physiologically counter-regulatory to insulin. Tesamorelin's FDA prescribing information carries a warning that glucose intolerance and diabetes can occur or worsen [4]. In the key trials, fasting glucose rose by a mean of 3.7 mg/dL in the tesamorelin group vs. 0.4 mg/dL in the placebo group.

Obtain a fasting glucose and HbA1c at baseline, at 8 weeks, and every 3 to 6 months thereafter. Patients with pre-diabetes (HbA1c 5.7 to 6.4%) may not be ideal candidates for this stack without close metabolic monitoring.

Other Safety Labs

• Thyroid function (TSH, free T4): GH stimulation can unmask central hypothyroidism.
• Morning cortisol: Same mechanism may reduce cortisol reserve in patients with borderline adrenal function.
• Lipid panel: Tesamorelin reduced triglycerides by 50 mg/dL (median) in the key HIV trials, a metabolically favorable effect [5].

Who Is (and Is Not) a Candidate

Patient selection for any GH-secretagogue stack requires physician evaluation of the full medical history. The FDA contraindications for tesamorelin are explicit [4]:

Contraindicated in:

• Active malignancy or a history of malignancy that could be stimulated by GH-axis activity
• Pituitary tumor or structural hypothalamic disease
• Pregnancy (teratogenic risk is unknown; GHRH crosses the placenta)
• Hypersensitivity to tesamorelin, mannitol, or sermorelin

Relative caution in:

• Type 2 diabetes or pre-diabetes (glucose monitoring required)
• Obstructive sleep apnea (GH excess worsens OSA)
• Active carpal tunnel syndrome (GH raises fluid retention)
• Age over 65 (IGF-1 targets shift; risk-benefit ratio changes)

The Endocrine Society's position on GH therapy in healthy older adults, stated in their 2019 clinical practice guideline, is direct: "We recommend against GH treatment for older patients without a diagnosis of GH deficiency" [6]. This applies with equal force to combination GHRH-secretagogue protocols in asymptomatic adults.

Side Effects Unique to the Combination

Each agent has a known side-effect profile individually. Stacking them may amplify specific effects.

Injection-Site Reactions

Tesamorelin injection-site reactions occurred in 24.5% of participants in the key trials [5]. Adding a second subcutaneous injection (sermorelin at night) doubles the daily injection burden and the cumulative skin-exposure area, raising the likelihood of localized erythema, pruritus, and nodule formation.

GH Excess Signs

Fluid retention, paresthesias in the hands, joint stiffness, and morning puffiness are the most common early signals that GH is running too high. If IGF-1 rises above the age-adjusted upper limit of normal and these symptoms appear together, reduce or pause sermorelin first (given its shorter half-life and off-label status), then recheck IGF-1 in 4 weeks.

Antibody Formation

The FDA label for tesamorelin notes that 49.5% of patients developed anti-tesamorelin antibodies over 52 weeks, though this did not appear to meaningfully reduce efficacy in most [4]. Sermorelin is immunogenic in a smaller proportion of patients. The combined immunogenicity data for the stack are unknown.

Evidence Gaps: What We Do Not Know

Direct honesty about evidence gaps is the standard of care here. These are the specific unknowns:

1. No RCT has compared sermorelin-plus-tesamorelin against either agent alone for any outcome.
2. The additive vs. Saturation question at the GHRH receptor has not been answered in human studies for this specific pair.
3. Long-term cancer risk data from GHRH-secretagogue stacking do not exist. A 2012 meta-analysis in JAMA linking elevated IGF-1 to colorectal and premenopausal breast cancer risk supports the biological plausibility of concern, even if causation is not established [9].
4. The optimal cycle length, off-cycle duration, and dose-titration schedule for the combination remain practitioner opinion, not evidence-based consensus.

Patients should receive this information in writing before starting the stack.

Practical Stacking Summary

The table below consolidates the protocol for clinical reference:

| Parameter | Tesamorelin (Egrifta SV) | Sermorelin (Compounded) | |---|---|---| | Dose | 2 mg | 200 to 300 mcg | | Route | Subcutaneous | Subcutaneous | | Timing | Morning, fasting preferred | Evening, near sleep onset | | Injection site | Abdominal rotation | Abdominal rotation | | Reconstitution | Per Egrifta SV kit | Bacteriostatic water | | Storage (reconstituted) | Discard within 24 h | 2 to 8°C, per compounder SOP | | Key monitoring | IGF-1, fasting glucose, HbA1c | IGF-1, TSH | | Cycle | Continuous per FDA protocol | Consider 4-wk break q 3 to 6 mo |

A specialist in endocrinology or hormone medicine should supervise this combination from initiation through monitoring. Tesamorelin is a Schedule-unclassified prescription drug; compounded sermorelin is dispensed through an FDA-registered 503A or 503B compounding pharmacy with a valid prescription only.